VCM
AKBA icon

Voleon Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Voleon Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$939K Buy
675,656
+404,354
+149% +$556K 0.02% 452
2025
Q4 		$437K Buy
271,302
+59,536
+28% +$125K 0.01% 605
2025
Q3 		$578K Buy
+211,766
New +$704K 0.01% 538

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Voleon Capital Management's AKBA Position: Q1 2026 in Review

Voleon Capital Management increased its Akebia Therapeutics (AKBA) stake by 149% in Q1 2026, buying an estimated $556K and bringing the position to 675,656 shares worth $939K. The position accounts for 0.02% of the portfolio, ranked #452.

Voleon Capital Management first reported a position in AKBA in Q3 2025 and has held it in 3 quarters since. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Voleon Capital Management held 675,656 shares of Akebia Therapeutics worth $939K as of Q1 2026.
  • Voleon Capital Management bought 404,354 Akebia Therapeutics shares in Q1 2026, an estimated $556K.
  • Akebia Therapeutics made up 0.02% of Voleon Capital Management's portfolio in Q1 2026, its #452 holding.
  • Voleon Capital Management first reported a position in Akebia Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.